↓ Skip to main content

Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study

Overview of attention for article published in Cardiovascular Diabetology, September 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
71 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study
Published in
Cardiovascular Diabetology, September 2016
DOI 10.1186/s12933-016-0438-x
Pubmed ID
Authors

Tatsuya Maruhashi, Yukihito Higashi, Yasuki Kihara, Hirotsugu Yamada, Masataka Sata, Shinichiro Ueda, Masato Odawara, Yasuo Terauchi, Kazuoki Dai, Jun Ohno, Masato Iida, Hiroaki Sano, Hirofumi Tomiyama, Teruo Inoue, Atsushi Tanaka, Toyoaki Murohara, Koichi Node, for the PROLOGUE Study Investigators

Abstract

As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes. In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment. HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively). Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes. University hospital Medical Information Network (UMIN) Center: ID UMIN000004490.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 1%
Unknown 70 99%

Demographic breakdown

Readers by professional status Count As %
Other 13 18%
Researcher 9 13%
Student > Bachelor 9 13%
Professor 6 8%
Student > Master 6 8%
Other 6 8%
Unknown 22 31%
Readers by discipline Count As %
Medicine and Dentistry 23 32%
Nursing and Health Professions 6 8%
Biochemistry, Genetics and Molecular Biology 3 4%
Sports and Recreations 2 3%
Social Sciences 2 3%
Other 6 8%
Unknown 29 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2017.
All research outputs
#15,384,302
of 22,888,307 outputs
Outputs from Cardiovascular Diabetology
#840
of 1,386 outputs
Outputs of similar age
#203,481
of 322,146 outputs
Outputs of similar age from Cardiovascular Diabetology
#16
of 28 outputs
Altmetric has tracked 22,888,307 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,386 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,146 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.